Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Perttu Koskenvesa

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Ejhaem|July 18, 2022
Ponatinib-induced ichthyosiform eruptionNicolas Kluger, Katriina Lappalainen, Perttu Koskenvesa
Duodecim; Laaketieteellinen Aikakauskirja|April 18, 2012
[Current therapy of chronic myeloid leukemia]Hanna Koskela, Perttu Koskenvesa, Satu Mustjoki, et al.
Patient Preference and Adherence|December 5, 2014
Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physiciansMeri Kekäle, Kimmo Talvensaari, Perttu Koskenvesa, et al.
Journal of Advanced Nursing|April 27, 2016
Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention studyMeri Kekäle, Tim Söderlund, Perttu Koskenvesa, et al.
Leukemia & Lymphoma|June 20, 2013
Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapyMette Ilander, Perttu Koskenvesa, Sari Hernesniemi, et al.
Ejhaem|November 29, 2023
Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in FinlandHeidi Loponen, Juha Mehtälä, Tero Ylisaukko-Oja, et al.
Leukemia Research|February 15, 2020
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapyStina Söderlund, Inger Persson, Mette Ilander, et al.
Leukemia|June 22, 2018
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CMLOscar Brück, Sami Blom, Olli Dufva, et al.
Blood Advances|February 12, 2020
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaShady Adnan Awad, Matti Kankainen, Teija Ojala, et al.
Blood Cancer Journal|April 21, 2022
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuationShady Adnan Awad, Oscar Brück, Naranie Shanmuganathan, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Ejhaem|July 18, 2022
Ponatinib-induced ichthyosiform eruptionNicolas Kluger, Katriina Lappalainen, Perttu Koskenvesa
Duodecim; Laaketieteellinen Aikakauskirja|April 18, 2012
[Current therapy of chronic myeloid leukemia]Hanna Koskela, Perttu Koskenvesa, Satu Mustjoki, et al.
Patient Preference and Adherence|December 5, 2014
Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physiciansMeri Kekäle, Kimmo Talvensaari, Perttu Koskenvesa, et al.
Journal of Advanced Nursing|April 27, 2016
Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention studyMeri Kekäle, Tim Söderlund, Perttu Koskenvesa, et al.
Leukemia & Lymphoma|June 20, 2013
Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapyMette Ilander, Perttu Koskenvesa, Sari Hernesniemi, et al.
Ejhaem|November 29, 2023
Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in FinlandHeidi Loponen, Juha Mehtälä, Tero Ylisaukko-Oja, et al.
Leukemia Research|February 15, 2020
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapyStina Söderlund, Inger Persson, Mette Ilander, et al.
Leukemia|June 22, 2018
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CMLOscar Brück, Sami Blom, Olli Dufva, et al.
Blood Advances|February 12, 2020
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaShady Adnan Awad, Matti Kankainen, Teija Ojala, et al.
Blood Cancer Journal|April 21, 2022
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuationShady Adnan Awad, Oscar Brück, Naranie Shanmuganathan, et al.
Pageof 3